A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

Inclusion criteria

• 1.18 ≤ age ≤45, healthy male; 2.Subjects with body weight ≥ 50 kg, and 19≤BMI ≤26 kg/m2 ； 3.Subjects must agree to take effective contraceptive methods from signing informed consent to 6 months after the last administration.

Exclusion criteria

• Subjects with known history or suspected of being allergic to the study drugs；
• Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening
• Subjects with eGFR less than 90 mL/min/1.73m2；
• Subjects with systolic blood pressure less than 90 mmHg or more than 140 mmHg, and/or diastolic blood pressure less than 60 mmHg or more than 90 mmHg;
• Subjects whoes12-Lead ECG QTcF was more than 450 ms or there were other abnormalities determined by the investigator；
• Subjects with clinically significant abnormalities in coagulation function；
• Subjects with infectious disease；
• Subjects with positive of urine drug screen；
• Subjects with acute illness occurred within 4 weeks prior to the screening period;
• Subjects who required antimicrobial therapy within 4 weeks prior to the screening period;
• Subjects with medical history of systemic inflammatory disease, autoimmune disease, recurrent herpes zoster, disseminated herpes zoster, disseminated herpes simplex;
• Subjects with a history of tuberculosis (TB) within six months prior to the screening period;
• Subjects with a history of hypoglycemic episodes or fasting blood glucose less than 2.8 mmol/L during screening；
• Subjects who took inhibitors or inducers of CYP3A4, CYP2C8, CYP2C9, or CYP2C19 within 28 days before the study;
• Subjects with contraindications for midazolam, warfarin, omeprazole, and repaglinide.